Best Practices for the Management of Patients with Non-Tuberculous Mycobacterial Pulmonary Disease According to a German Nationwide Analysis of Expert Centers.

Germany NTM best practices interviews management pulmonary treatment centers

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
22 Sep 2023
Historique:
received: 18 04 2023
revised: 14 09 2023
accepted: 20 09 2023
medline: 13 10 2023
pubmed: 13 10 2023
entrez: 13 10 2023
Statut: epublish

Résumé

Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic inflammatory lung disease caused by infection with non-tuberculous mycobacteria (NTM). International guidelines provide evidence-based recommendations on appropriate diagnosis and treatment strategies, but there is a need for sharing day-to-day best practice between treatment centers to optimize patient care. This is particularly valuable for rare diseases like NTM-PD. In this cross-sectional analysis of NTM-PD management in Germany, medical and administrative staff from seven treatment centers were interviewed to identify best practice in the diagnosis, treatment, and ongoing management of patients with NTM-PD, including related hospital infrastructure and administration processes. A prioritization led to a collection of best practices for the management of patients with NTM-PD in Germany, which is presented here. Selected current best practices included performance of regular sputum tests for diagnosis, use of medical reports, and regular follow-up visits as well as increased interaction between physicians across different specialties. Future best practices that may be implemented to overcome current barriers comprised disease awareness activities, patient empowerment, and new approaches to enhance physician interaction. Challenges related to their implementation are also discussed and will help to raise disease awareness. The presented best practices may guide and optimize patient management in other centers.

Identifiants

pubmed: 37830647
pii: healthcare11192610
doi: 10.3390/healthcare11192610
pmc: PMC10572995
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : CSRD VA
ID : 1
Pays : United States

Références

Respir Med. 2015 Jan;109(1):137-45
pubmed: 25464905
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 33542057
Clin Infect Dis. 2020 Aug 14;71(4):e1-e36
pubmed: 32628747
ERJ Open Res. 2021 Feb 15;7(1):
pubmed: 33614773
Ther Adv Med Oncol. 2022 Oct 31;14:17588359221127681
pubmed: 36339928
Emerg Infect Dis. 2016 Jun;22(6):1102-5
pubmed: 27191473
Patient Prefer Adherence. 2016 Apr 28;10:711-25
pubmed: 27175071
Life (Basel). 2023 Apr 10;13(4):
pubmed: 37109507
Curr Pulmonol Rep. 2018 Dec;7(4):126-132
pubmed: 31106117
PLoS One. 2017 Nov 20;12(11):e0188348
pubmed: 29155870
Adv Ther. 2020 Jun;37(6):2999-3009
pubmed: 32333326
J Korean Med Sci. 2016 May;31(5):649-59
pubmed: 27134484
Eur Respir J. 2020 Oct 1;56(4):
pubmed: 32430411
J Appl Microbiol. 2009 Aug;107(2):356-67
pubmed: 19228258
Thorax. 2009 Jun;64(6):502-6
pubmed: 19213773
BMC Infect Dis. 2018 May 3;18(1):206
pubmed: 29724184
Eur J Clin Microbiol Infect Dis. 2015 Sep;34(9):1909-18
pubmed: 26155783
Respir Med. 2011 Nov;105(11):1718-25
pubmed: 21868209
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Respir Med. 2020 Nov;173:106164
pubmed: 32992265
Br J Radiol. 2020 Feb 1;93(1106):20190768
pubmed: 31794241
Eur Respir J. 2017 Feb 15;49(2):
pubmed: 28182571
Thorax. 2007 Aug;62(8):661-6
pubmed: 17311842
Am J Respir Crit Care Med. 2015 Sep 1;192(5):618-28
pubmed: 26038974
J Clin Tuberc Other Mycobact Dis. 2020 Aug 06;20:100178
pubmed: 32802970
Br J Cancer. 2015 Jan 6;112(1):207-16
pubmed: 25461805
Internist (Berl). 2022 Mar;63(3):255-265
pubmed: 35181796
Am J Respir Crit Care Med. 2012 Sep 15;186(6):553-8
pubmed: 22773732
Pneumologie. 2013 Nov;67(11):605-33
pubmed: 24198237
Clin Microbiol Rev. 2004 Jan;17(1):98-106
pubmed: 14726457
BMJ Open Respir Res. 2020 Jun;7(1):
pubmed: 32565445
Int J Infect Dis. 2021 Mar;104:398-406
pubmed: 33444748

Auteurs

Gernot Rohde (G)

Pneumologie/Allergologie, Medizinische Klinik 1, Universitätsklinikum Frankfurt, Goethe-Universität, 60590 Frankfurt am Main, Germany.

Monika Eichinger (M)

Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), 69120 Heidelberg, Germany.
Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik, Heidelberg University Hospital, 69126 Heidelberg, Germany.

Sven Gläser (S)

Vivantes Klinikum Neukölln und Spandau, Klinik für Innere Medizin-Pneumologie und Infektiologie, 13585 Berlin, Germany.

Marion Heiß-Neumann (M)

Department of Pneumology, Asklepios Lungenfachklinik München-Gauting, 82131 Gauting, Germany.

Jan Kehrmann (J)

Institute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.

Claus Neurohr (C)

Robert-Bosch-Krankenhaus Klinik Schillerhöhe-Lungenzentrum Stuttgart, 70376 Stuttgart, Germany.

Marko Obradovic (M)

Insmed Germany GmbH, 60549 Frankfurt am Main, Germany.

Tim Kröger-Kilian (T)

Insmed Germany GmbH, 60549 Frankfurt am Main, Germany.

Tobias Loebel (T)

Insmed Germany GmbH, 60549 Frankfurt am Main, Germany.

Christian Taube (C)

Department of Pulmonary Medicine, Ruhrlandklinik, University Hospital Essen, 45239 Essen, Germany.

Classifications MeSH